CYP2C19 and Stroke: Recently, genetic testing in medicine has provided a new possibility for personalized medicine: the genetic sub-study of the CHANCE trial revealed that aspirin-clopidogrel only reduced the risk of stroke recurrence in non-carriers of the CYP2C19 loss-of-function allele (8).